


## PHARMACEUTICAL 2021



## Xencor Inc Rank 62 of 409







## PHARMACEUTICAL 2021



## Xencor Inc Rank 62 of 409



The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 136% points. The greatest weakness of Xencor Inc is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 83%, being 438% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	637,672
Cost of Goods Sold	0
Intangible Assets	15,977
Liabilities, Current	121,061
Liabilities, Non-Current	9,739
Other Assets	27,913
Other Compr. Net Income	-1,087
Other Expenses	0
Other Liabilities	0
Other Net Income	7,464
Property and Equipment	21,682
Research and Development	169,802
Revenues	122,694
Selling, General and Administrative Expense	29,689

Output Variable	Value in 1000 USD
Assets	703,244
Liabilities	130,800
Expenses	199,491
Stockholders Equity	572,444
Net Income	-69,333
Comprehensive Net Income	-69,876
Economic Capital Ratio	83%